Photo by neom from unsplash
Abstract Studies over the past few decades demonstrate the potential for metallodrugs as bioactive therapeutics. Here, we describe six new ruthenium(II) complexes with the general motif of (η6-p-cymene)Ru(NH2R)X2, where NH2R… Click to show full abstract
Abstract Studies over the past few decades demonstrate the potential for metallodrugs as bioactive therapeutics. Here, we describe six new ruthenium(II) complexes with the general motif of (η6-p-cymene)Ru(NH2R)X2, where NH2R is either the influenza A antiviral drugs rimantadine or amantadine or the N-methyl-D-aspartate [NMDA] receptor antagonist, memantine and X = Cl or Br. All complexes were synthesized in high yield and purity and characterized by NMR spectroscopy and X-ray crystallography. Both the chlorine and bromine ruthenium(II) p-cymene complexes demonstrated cellular toxicity profiles similar to their respective free ligand, indicating that complexation to ruthenium(II) centers does not significantly increase toxicity of the bioactive ligand.
Journal Title: Polyhedron
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!